title: Beyond platinum treatment for NSCLC: what does the future hold?
authors.affiliation: a Medical Oncology Unit, Department of Human Pathology 'G. Barresi' , University of Messina , Messina , Italy.
authors.forename: Mariacarmela
authors.initials: M
authors.lastname: Santarpia
authors.affiliation: b Institute of Oncology Rosell (IOR) , University Hospital Sagrat Cor , Barcelona , Spain.
authors.forename: Niki
authors.initials: N
authors.lastname: Karachaliou
authors.affiliation: c Institute of Oncology Rosell (IOR), Quirón-Dexeus University Institute , Barcelona , Spain.|d Cancer Biology & Precision Medicine Program , Catalan Institute of Oncology, Hospital Germans Trias i Pujol , Badalona , Barcelona , Spain.|e Cellular and Molecular Biology Laboratory, Germans Trias i Pujol Health Sciences Institute and Hospital , Badalona , Barcelona , Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D015195:Drug Design; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D058990:Molecular Targeted Therapy; D017671:Platinum Compounds / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D017671:Platinum Compounds
keywords: Non-small cell lung cancer (NSCLC); immune checkpoint blockade; immunotherapy; nivolumab; pembrolizumab